The losers are pil­ing up af­ter to­day’s big ASH ab­stract drop

To­day is the big drop for ASH ab­stracts, and Spark $ONCE isn’t the on­ly biotech com­pa­ny to be dam­aged in the re­sponse to some of the safe­ty warn­ings or weak re­sults to hit the biotech cir­cuit on Twit­ter.

Tril­li­um Ther­a­peu­tics crushed

Tril­li­um Ther­a­peu­tics $TRIL gets the boo­by-trap prize af­ter see­ing its shares lose about half their val­ue on a safe­ty warn­ing from their Phase I study of the CD47 drug TTI-621.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER